Effect of cisplatin on expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and their correlations in Lewis lung cancer in mice

Chinese Journal of Cancer

Volumn 28, Issue 7, 2009, Pages

  Li, Chun Jie ^a   Sun, Jian Li ^a   Jiang, Wei Jie ^a   Liu, Ling Shuang ^a   Sun, Xi Yuan ^a   Fan, Guo Zhong ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Cisplatin; Lewis lung cancer; Metastasis; MMP 9; Mouse; TIMP 1

Indexed keywords

CISPLATIN; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CANCER INHIBITION; CANCER INVASION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOHISTOCHEMISTRY; LEWIS CARCINOMA; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR VOLUME;

EID: 79955784867     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.009.10025     Document Type: Article

References (15)

1. Li LY. Lung cancer [J]. Oncol Progress, 2005, 3 (2): 114. [in Chinese]
2. Gouyer V, Conti M, Devos P, et al. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with non-small cell lung carcinoma who undergo resection with curative intent [J]. Cancer, 2005, 103(8): 1676-1684.
3. Aljada IS, Ramnath N, Donohue K, et al. Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer [J]. J Clin Oncol, 2004, 22(16): 3218-3229.
4. Hansen HH. Lung Cancer [M]. Wang Z, Li HW, translator. Shenyang: Press of Science and Technology, 2001: 27. [in Chinese]
5. Hoekstra R, Eskens FA, Verweij J. Matrix Metalloproteinase Inhibitors: Current Developments and Future Perspectives [J]. Oncologist, 2001, 6(5): 415-416.
6. Stetler-Stevenson WG, Liotta LA, Kleiner DE Jr. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis [J]. FASEB J, 1993, 7(12): 1434-1441.
7. Ennis BW, Matrisian LM. Matrix degrading metalloproteinases [J]. J Neurooncol, 1994, 18(2): 105-109.
8. Ashida K, Nakatsukasa H, Higashi T, et al. Cellular distribution of 92-kd type IV collagenase/gelatinase B in human hepatocellular carcinoma [J]. Am J Pathol, 1996, 149 (12): 1803-1811.
9. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations [J]. Science, 2002, 295(3): 2387-2390.
10. Wang XY, Yang JH, Ma Y, et al. Expression and significance of matrix metalloproteinase and their tissue inhibitors in the infiltration and metastasis of lung cancer [J]. Chin J Lung Cancer, 2003.8, 6(4): 278-282. [in Chinese]
11. Gu YY, Liu F, Chen GQ, et al. The relationship between the expression of MMPs and TIMPs and metastasis and prognosis in no-small cell lung cancer [J]. Chin Trop Med, 2006, 6(11): 1949-1952. [in Chinese]
12. Liang J, Liu MQ, Xie M, et al. Expressions of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 and their correlation with metastasis and prognosis in lung cancer [J]. Chin J Lung Cancer, 2003, 6(1): 46-51. [in Chinese]
13. Iizasa T, Fujisawa T, Suzuki M, et al. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients [J]. Clin Cancer Res, 1999, 5(1): 149-152.
14. Jumper C, Cobos E, Lox C. Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment [J]. Respir Med, 2004, 98(2): 173-177.
15. Ylisirniö S, Höyhtyä M, Turpeenniemi-Hujanen T. Serum matrix metalloproteinases 2, 9 and tissue inhibitors of metalloproteinases 1, 2 in lung cancer-TIMP-1 as a prognostic marker [J]. Anticancer Res, 2000, 20(2B): 1311-1316.